Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03001882 | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)(CheckMate 592) | completed | Phase 2 | 230 | Bristol-Myers SquibbINDUSTRY | 8 | May 20, 2024 | clinicaltrials |
| NCT02978196 | 99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC | completed | Early Phase 1 | 34 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER |
| 1 |
| May 17, 2024 |
| clinicaltrials |
| NCT02910999 | Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy(ENLARGE-Lung) | completed | — | 868 | Bristol-Myers SquibbINDUSTRY | 1 | May 13, 2024 | clinicaltrials |
| NCT01941316 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 78 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | May 9, 2024 | clinicaltrials |
| NCT03712969 | Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC | completed | Phase 4 | 527 | West China HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT03810066 | Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) | completed | Phase 2 | 16 | University Hospital, EssenOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04263090 | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | completed | Phase 1 / Phase 2 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT02225405 | Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04324437 | eRAPID: Online Symptom Reporting in Lung Cancer | completed | N/A | 43 | University of LeedsOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT03117049 | Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) | completed | Phase 3 | 550 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 6, 2024 | clinicaltrials |
| NCT03946007 | Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors | completed | — | 134 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01928576 | Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.(NA_00084192) | completed | Phase 2 | 143 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02658097 | Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02760225 | Pembrolizumab-PET Imaging | completed | N/A | 18 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04967079 | Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | completed | Phase 1 | 33 | Shanghai Chest HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT02118415 | Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT) | completed | Phase 2 | 13 | Technical University of MunichOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03861156 | D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | completed | Phase 2 | 290 | InventisBio Co., LtdINDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT03490669 | Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 3 | Apr 5, 2024 | clinicaltrials |
| NCT04511533 | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | completed | Phase 4 | 101 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04979988 | Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients | completed | — | 51 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT03866993 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 350 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03958097 | Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer | completed | Phase 2 | 20 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04501497 | Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2) | completed | — | 1,221 | Chugai PharmaceuticalINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04818983 | The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2) | completed | — | 470 | Chugai PharmaceuticalINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06339554 | Alectinib-induced Endocrine Toxicity(TOSS-ALK) | completed | — | 98 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT01761240 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Mar 29, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02581787 | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 28 | Maximilian DiehnOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06331975 | Radiomics and Radiogenomics of Non-small Cell Lung Cancer | completed | N/A | 91 | European Institute of OncologyOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT03017885 | Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy | completed | — | 28 | Boehringer IngelheimINDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02337530 | Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC | completed | Phase 2 | 62 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02414139 | Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) | completed | Phase 2 | 373 | Novartis PharmaceuticalsINDUSTRY | 20 | Mar 20, 2024 | clinicaltrials |
| NCT04212052 | Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03535363 | Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC | completed | Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT03607188 | Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer(NSCLC) | completed | Phase 1 | 17 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04310943 | Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma | completed | Phase 2 | 24 | Zhou ChengzhiOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT00019006 | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00020202 | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03976518 | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)(CHANCE) | completed | Phase 2 | 43 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT01540045 | Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer | completed | — | 40 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04238169 | Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC | completed | Phase 2 | 60 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05005273 | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 12 | Feb 28, 2024 | clinicaltrials |
| NCT02869685 | Consistency Analysis of PD-L1s in Advanced NSCLC Tissues and in Plasma Exosomes Before and After Radiotherapy(RadImm02) | completed | N/A | 60 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT02890849 | Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome(RadImm01) | completed | N/A | 60 | Xinqiao Hospital of ChongqingOTHER | 0 | Feb 23, 2024 | clinicaltrials |
| NCT02922777 | Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. | completed | Phase 1 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03643484 | IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy | completed | — | 634 | AstraZenecaINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04676009 | Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients(ERICA) | completed | N/A | 26 | Centre Leon BerardOTHER | 1 | Feb 21, 2024 | clinicaltrials |
Data updated 24 days agoSource updated May 20, 2024source: clinicaltrials